Background: Recently, Cp and Temozolamide (Tz) treatment has been investigated in NET in several studies, with heterogeneous populations and outcomes. Cp plus Tz reported a median PFS of about 13 months and it seems more efficient in pancreatic NET. Results from phase II and non-randomized trials with fluoropyrimidine in combination with SSA in well-differentiated (WD) NET are limited, and considered investigational.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile